UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 29, 2020
ALIMERA SCIENCES, INC.
(Exact name of registrant as specified in its charter)
Delaware
 
001-34703
 
20-0028718
(State or other Jurisdiction of Incorporation)
 
(Commission File Number)
 
(IRS Employer Identification No.)
 
 
 
6120 Windward Parkway
Suite 290
Alpharetta, Georgia
 
30005
(Address of Principal Executive Offices)
 
(Zip Code)

Registrant’s telephone number, including area code: (678) 990-5740
Not Applicable
(Former name or former address if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.01 par value per share
ALIM
The Nasdaq Stock Market LLC
(Nasdaq Global Market)
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  o



Item 2.02. Results of Operations and Financial Condition.
On April 29, 2020, Alimera Sciences, Inc. (“Alimera”) issued a press release regarding its results of operations and financial condition for the first quarter ended March 31, 2020 as well as a corporate update. On April 30, 2020 at 9:00 A.M. ET, Alimera will host a conference call and a live webcast on the Investor Relations section of its corporate website at www.alimerasciences.com. During the conference call, Alimera’s executives will discuss its financial results for the first quarter ended March 31, 2020 and provide commercial and other corporate updates, including the impact of COVID-19 on Alimera. The full text of the press release, which includes information regarding Alimera’s use of a non-GAAP financial measure, is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
In the press release, we included the following statement: “End user demand, which represents units purchased by physicians and pharmacies from Alimera’s U.S. distributors, decreased in Q1 2020 to 855 units compared to 973 units in Q1 2019 due to the impact from the COVID-19 virus pandemic late in the first quarter, as well as a temporary shortage in stock in the U.S. in the first quarter.” The reference to “973 units” in this sentence should have been to “939 units.”
Various statements made during the conference call and webcast will or may be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, regarding, among other things, Alimera’s expectations regarding (a) its plans to prepare for, and its intentions to maximize, its business performance once the pandemic has abated, (b) sales of ILUVIEN® in the second quarter, (c) the continuance of the current circumstances for patient visits with their physicians and the effects of those circumstances, (d) the sufficiency of Alimera’s inventory and supply chain to meet demand for ILUVIEN, (e) opportunities for the sale of ILUVIEN when patient visits resume at a more normal level (and if a second wave of COVID-19 infection occurs), (f) the adoption by physicians of a therapy like ILUVIEN that requires fewer office visits than short-acting treatments, (g) Alimera’s modification of its operational activities and the effect of those modifications, (h) Alimera’s intention to retain its personnel to serve physicians when access is restored, and (i) its corporate priorities for growth and expansion. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change them, and could cause actual results to differ materially from those projected in the forward-looking statements. Meaningful factors that could cause actual results to differ include, but are not limited to,

•
uncertainty about the impact of COVID on Alimera’s revenue, the duration of the pandemic, Alimera’s ability to manage its expenses and whether it can manage those expenses sufficiently to mitigate the loss of revenue;
•
other adverse effects of COVID-19 in the regions where Alimera has customers, employees and distributors;
•
the adverse effects of COVID-19 on sales of ILUVIEN resulting from (a) limitations on in-person access to physicians and (b) the unwillingness of patients, many of whom suffer from diabetic macular edema, to visit their physicians in person due to their fear of contracting COVID-19;
•
Alimera’s ability retain its personnel, given the uncertain COVID-19 environment and the currently decreased level of sales of ILUVIEN;
•
the effects of limitations on travel within and between the countries in which Alimera markets and sells ILUVIEN, as well as various types of “shelter in place” orders, which have curtailed our in-person marketing activities;
•
the possibility that Alimera may fail to plan appropriately to meet the demand of its customers for ILUVIEN, which could lead either to (a) ILUVIEN being out of stock or (b) Alimera’s investment of a greater amount of cash in inventory than needed; or
other unexpected circumstances, and other factors discussed in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Alimera’s Annual Report on Form 10-K for the year ended December 31, 2019, which are on file with the Securities and Exchange Commission (SEC) and available on the SEC’s website at http://www.sec.gov. Additional factors will also be described in those sections of Alimera’s Quarterly Report on Form 10-Q for the first quarter of 2020, to be filed with the SEC soon.
In addition to the risks described above and in Alimera’s reports and other filings with the SEC, other unknown or unpredictable factors also could affect Alimera’s results. There can be no assurance that the actual results or developments anticipated by Alimera will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Alimera. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved. All forward-looking statements contained in the conference call and webcast and in the press release are expressly qualified by the cautionary statements contained or referred to herein. These forward-looking statements speak only as of the date of the conference call and webcast and the press release (unless another date is indicated). Alimera undertakes no obligation, and specifically declines any obligation, to publicly update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
The information in Item 2.02 of this Current Report on Form 8-K and the press release furnished as Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such a filing.

1


Item 7.01. Regulation FD.
The conference call and webcast, and the press release, include or will include a non-GAAP financial measure, Adjusted EBITDA. A reconciliation of this non-GAAP financial measure to the comparable measure calculated and presented in accordance with GAAP is included in Alimera’s press release issued April 29, 2020 and attached hereto as Exhibit 99.1.
The information in this Current Report on Form 8-K under Item 7.01 is being “furnished” and not “filed” with the SEC for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities under such section. Furthermore, such information shall not be deemed incorporated by reference in any filing under the Securities Act, or the Exchange Act, unless specifically identified as being incorporated therein by reference.

2


Item 9.01. Financial Statements and Exhibits.
(d)    Exhibits

Exhibit
No.
 
Description
99.1
 














3



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
ALIMERA SCIENCES, INC.
 
 
 
Dated: April 29, 2020
By:
/s/ J. Philip Jones
 
Name:
J. Philip Jones
 
Title:
Chief Financial Officer



4
Exhibit

Exhibit 99.1



FOR IMMEDIATE RELEASE


Alimera Sciences Announces First Quarter 2020 Financial Results and Provides Corporate Update

First Quarter and Recent Company Highlights:
•
Consolidated Net Revenue Up 12% Compared to First Quarter 2019
•
International Net Revenue Up 23% Compared to First Quarter 2019
•
Net Loss of $1.2 Million vs. Net Loss of $2.8 million in First Quarter 2019
•
$1.3 Million Positive Adjusted EBITDA

ATLANTA (April 29, 2020) – Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces financial results for the three months ended March 31, 2020. Alimera will host a conference call on Thursday, April 30, 2020 at 9:00 AM ET to review these financial results and provide an update on corporate developments.

“I want to recognize both our employees who have addressed the challenges of COVID-19 with great energy and dedication and the retina physicians and their staffs around the world who are serving patients during this difficult time. As for the first quarter results, we are pleased to report consolidated revenue of $14.5 million, a 12% gain over the first quarter of last year. We also narrowed our GAAP net loss by 57% while achieving $1.3 million in positive adjusted EBITDA despite the advent of the coronavirus pandemic in the quarter,” said Rick Eiswirth, Alimera’s President and Chief Executive Officer. Mr. Eiswirth continued: “With the onset of COVID-19 in the regions where we operate, our access to physicians, and patients’ willingness to visit physicians, has become limited, especially for diabetic patients who have been advised they are at higher risk for severe illness from COVID-19. With very little in-person access to physicians and hospitals, it has been challenging or impossible for our sales representatives to meet with retina specialists and their staff to educate them about the benefits of ILUVIEN©. These limitations and other effects of COVID-19 had a material adverse impact on our revenues late in the first quarter and in the month of April. We expect these factors to continue to adversely impact our revenue, but the extent and duration of that impact is uncertain at this time. Therefore, we are aggressively managing our non-payroll expenses to mitigate this loss of revenue and retain our personnel to serve physicians when access is restored.”
Mr. Eiswirth further observed, regarding ILUVIEN: “We believe that the COVID-19 experience highlights the benefits of ILUVIEN as a non-acute therapy treating diabetic macular edema and uveitis consistently and continuously for up to three years while reducing the recurrence of these diseases. As more patients begin to return to physician clinics, we expect physicians will need to manage through a significant backlog of patients and will consider reducing the risk of


COVID-19 exposure to patients by adopting a therapy like ILUVIEN that requires fewer office visits than short-acting treatments.”
First Quarter 2020 Financial Results

Consolidated Net Revenue
Consolidated net revenue for Q1 2020 grew 12% to $14.5 million, compared to $12.9 million for Q1 2019.

U.S. net revenue was $7.1 million for Q1 2020, up 4% from $6.8 million during the same period in 2019. End user demand, which represents units purchased by physicians and pharmacies from Alimera’s U.S. distributors, decreased in Q1 2020 to 855 units compared to 973 units in Q1 2019 due to the impact from the COVID-19 virus pandemic late in the first quarter, as well as a temporary shortage in stock in the U.S. in the first quarter. There was no material increase in the stock levels held by the company’s U.S. distributors during the quarter, as sales to distributors only differed from end user demand by approximately 3%.

International net revenue increased 23% to approximately $7.5 million in Q1 2020, compared to approximately $6.1 million for the same period during 2019, driven primarily by growth in our DME business in Alimera’s direct markets as well as the launches of ILUVIEN’s uveitis indication in Germany and the U.K. in the second half of 2019.

Operating Expenses
Total operating expenses for Q1 2020 decreased by $0.3 million or 2% to $12.4 million, compared to $12.7 million during Q1 2019.

Net Loss and Non-GAAP Adjusted EBITDA
For Q1 2020, Alimera reported a net loss of approximately $1.2 million, compared to a net loss of $2.8 million for Q1 2019. “Adjusted EBITDA,” a non-GAAP financial measure defined below, was approximately $1.3 million for Q1 2020, compared to approximately $27,000 for Q1 2019.

Net Loss per Share
Basic and diluted net loss per share for Q1 2020 was $0.24. This compares to basic and diluted net loss per share for Q1 2019 of $0.59.

Cash and Cash Equivalents
On February 24, 2020, Alimera announced that it had drawn down the remaining $2.5 million under the $45 million term loan agreement with its current lenders, investment affiliates managed by Solar Capital Partners, LLC. Under the terms of the agreement, Alimera had the option to draw down an additional $2.5 million if it achieved $30.0 million in revenue for any trailing six-month period ending on or before November 30, 2020. The $2.5 million loan brings the total Alimera borrowings under the agreement to the maximum $45 million available.

As of March 31, 2020, Alimera had cash and cash equivalents of approximately $12.2 million, compared to $9.4 million in cash and cash equivalents as of December 31, 2019.



On April 23, 2020, Alimera announced that it received on April 22, 2020 approximately $1.8 million in support from the federal government under the Paycheck Protection Program.
Definition of Non-GAAP Financial Measure
For purposes of this press release, “Adjusted EBITDA” is defined as earnings before interest, taxes, depreciation, amortization, stock-based compensation expenses, net unrealized gains and losses from foreign currency exchange transactions, losses on extinguishment of debt and severance expenses. Please refer to the sections of this press release entitled “Non-GAAP Financial Measure” and “Reconciliation of GAAP Net Loss to Non-GAAP Adjusted EBITDA.”

Conference Call to Be Held April 30, 2020
A live conference call will be hosted on April 30, 2020 at 9:00am eastern time by Rick Eiswirth, President and Chief Executive Officer, and Phil Jones, Chief Financial Officer, to discuss Alimera’s financial results. Please refer to the information below for conference call dial-in information and webcast registration.

Conference date: Thursday April 30, 2020 9:00 AM ET
Conference dial-in: 866-777-2509
International dial-in: 412-317-5413
Conference Call Name: Alimera Sciences (Nasdaq: ALIM) First Quarter 2020 Financial Results and Corporate Update Conference Call
Conference Call Pre-registration: 
Participants can register for the conference by navigating to http://dpregister.com/10142450
Please note that registered participants will receive their dial in number upon registration and will dial directly into the call without delay.
Live Webcast URL: https://services.choruscall.com/links/alimera200430.html

A replay will be available on Alimera’s website, www.alimerasciences.com, under “Investor Relations” one hour following the live call.
Conference Call replay: US Toll Free: 1-877-344-7529
International Toll: 1-412-317-0088
Canada Toll Free: 855-669-9658
Replay Access Code: 10142450
End Date: May 14, 2020
About Alimera Sciences, Inc.
www.alimerasciences.com
Alimera is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and affect millions of people globally. For more information, please visit www.alimerasciences.com.




Non-GAAP Financial Measure
This press release contains a discussion of a non-GAAP financial measure, as defined in Regulation G promulgated under the Securities Exchange Act of 1934, as amended. Alimera reports its financial results in compliance with GAAP but believes that the non-GAAP measure of Adjusted EBITDA provides useful information to investors regarding Alimera’s operating performance. Alimera uses Adjusted EBITDA in the management of its business. Accordingly, Adjusted EBITDA for the three months March 31, 2020 has been presented in certain instances excluding items identified in the reconciliations provided in the table entitled “Reconciliation of GAAP Net Loss to non-GAAP Adjusted EBITDA.” GAAP net loss is the most directly comparable GAAP financial measure to Adjusted EBITDA.
Adjusted EBITDA, as presented, may not be comparable to similarly titled measures reported by other companies because not all companies may calculate Adjusted EBITDA in an identical manner. Therefore, Adjusted EBITDA is not necessarily an accurate measure of comparison between companies.
The presentation of Adjusted EBITDA is not intended to be considered in isolation or as a substitute for guidance prepared in accordance with GAAP. The principal limitation of this non-GAAP financial measure is that it excludes significant elements required by GAAP to be recorded in Alimera’s financial statements. In addition, Adjusted EBITDA is subject to inherent limitations as it reflects the exercise of judgments by management in determining this non-GAAP financial measure.
About ILUVIEN
ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg is a sustained release intravitreal implant, injected into the back of the eye. With its CONTINUOUS MICRODOSING™ technology, ILUVIEN is designed to release submicrogram levels of fluocinolone acetonide, a corticosteroid, for up to 36 months, to reduce the recurrence of disease, enabling patients to maintain vision longer with fewer injections. ILUVIEN is approved in the U.S., Canada, Kuwait, Lebanon and the U.A.E. to treat diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. In 17 European countries, ILUVIEN is indicated for the treatment of vision impairment associated with chronic DME considered insufficiently responsive to available therapies and for prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIPU). Alimera does not have the contractual right to pursue approval to treat uveitis in the U.S., and therefore does not have a regulatory license in the U.S. to treat NIPU. For important safety information on ILUVIEN, see https://iluvien.com/#isi

Forward Looking Statements
This press release contains, and the remarks by Alimera’s officers on the conference call may contain, “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, regarding, among other things, Alimera’s expectations regarding (a) the


level of sales in this quarter, (b) the continuance of the current circumstances for patient visits with their physicians and the effects of those circumstances, (c) opportunities for the sale of ILUVIEN when patient visits resume at a more normal level, (d) Alimera’s modification of its operational activities and the effect of those modifications, and (e) Alimera’s intention retain its personnel to serve physicians when access is restored. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change them, and could cause actual results to differ materially from those projected in the forward-looking statements. Meaningful factors that could cause actual results to differ include, but are not limited to,
•
uncertainty about the impact of COVID on Alimera’s revenue, the duration of the pandemic, Alimera’s ability to manage its expenses and whether it can manage those expenses sufficiently to mitigate the loss of revenue;
•
other adverse effects of COVID-19 in the regions where Alimera has customers, employees and distributors;
•
the adverse effects of COVID-19 on sales of ILUVIEN resulting from (a) limitations on in-person access to physicians and (b) the unwillingness of patients, many of whom suffer from diabetic macular edema, to visit their physicians in person due to their fear of contracting COVID-19;
•
Alimera’s ability to retain its personnel, given the uncertain COVID-19 environment and the anticipated lower level of sales of ILUVIEN or
other unexpected circumstances, and other factors discussed in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Alimera’s Annual Report on Form 10-K for the year ended December 31, 2019, which are on file with the Securities and Exchange Commission (SEC) and available on the SEC’s website at http://www.sec.gov. Additional factors will also be described in those sections of Alimera’s Quarterly Report on Form 10-Q for the first quarter of 2020, to be filed with the SEC soon.
The forward-looking statements in this press release speak only as of the date of this press release (unless another date is indicated). Alimera undertakes no obligation, and specifically declines any obligation, to publicly update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
For investor inquiries:


 

For media inquiries:

Scott Gordon
Jules Abraham
for Alimera Sciences 
for Alimera Sciences 
scottg@coreir.com 
julesa@coreir.com

# # #




ALIMERA SCIENCES, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands)
 
March 31,
2020
 
December 31,
2019
 
(unaudited)
 
 
CURRENT ASSETS:
 
 
 
Cash and cash equivalents
$
12,242
 
$
9,426
Restricted cash
31
 
33
Accounts receivable, net
16,179
 
19,331
Prepaid expenses and other current assets
2,497
 
2,565
Inventory
1,196
 
1,390
Total current assets
32,145
 
32,745
NON-CURRENT ASSETS:
 
 
 
Property and equipment, net
867
 
940
Right of use assets, net
967
 
1,107
Intangible asset, net
14,299
 
14,783
Deferred tax asset
720
 
734
TOTAL ASSETS
$
48,998
 
$
50,309
CURRENT LIABILITIES:
 
 
 
Accounts payable
$
5,833
 
$
7,077
Accrued expenses
3,045
 
4,716
Finance lease obligations
243
 
255
Total current liabilities
9,121
 
12,048
NON-CURRENT LIABILITIES:
 
 
 
Note payable, net of discount
41,395
 
38,658
Finance lease obligations — less current portion
97
 
94
Other non-current liabilities
3,789
 
3,954
COMMITMENTS AND CONTINGENCIES
 
 
 
STOCKHOLDERS’ DEFICIT:
 
 
 
Preferred stock:
 
 
 
Series A Convertible Preferred Stock
19,227
 
19,227
Series C Convertible Preferred Stock
11,117
 
11,117
Common stock
50
 
50
Additional paid-in capital
350,442
 
350,117
Common stock warrants
3,707
 
3,707
Accumulated deficit
(388,768)
 
(387,570)
Accumulated other comprehensive loss
(1,179)
 
(1,093)
TOTAL STOCKHOLDERS’ DEFICIT
(5,404)
 
(4,445)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT
$
48,998
 
$
50,309





ALIMERA SCIENCES, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE THREE MONTHS ENDED MARCH 31, 2020 AND 2019
(in thousands, except share and per share data)

 
Three Months Ended
March 31,
 
2020
 
2019
 
(Unaudited)
 
 
 
 
 
 
NET REVENUE
$
14,535
 
$
12,890
COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION
(1,927)
 
(1,600)
GROSS PROFIT
12,608
 
11,290
 
 
 
 
RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES
2,883
 
2,727
GENERAL AND ADMINISTRATIVE EXPENSES
3,181
 
3,393
SALES AND MARKETING EXPENSES
5,672
 
5,913
DEPRECIATION AND AMORTIZATION
654
 
652
OPERATING EXPENSES
12,390
 
12,685
NET INCOME (LOSS) FROM OPERATIONS
218
 
(1,395)
 
 
 
 
INTEREST EXPENSE AND OTHER
(1,292)
 
(1,228)
UNREALIZED FOREIGN CURRENCY LOSS, NET
(81)
 
(69)
NET LOSS BEFORE TAXES
(1,155)
 
(2,692)
PROVISION FOR TAXES
(43)
 
(71)
NET LOSS
$
(1,198)
 
$
(2,763)
NET LOSS PER SHARE — Basic and diluted
$
(0.24)
 
$
(0.59)
WEIGHTED AVERAGE SHARES OUTSTANDING — Basic and diluted
4,980,722
 
4,716,054





ALIMERA SCIENCES, INC.
REPORTABLE SEGMENT INFORMATION
FOR THE THREE MONTHS ENDED MARCH 31, 2020 AND 2019
(in thousands)
 
Three Months Ended
March 31, 2020
 
Three Months Ended
March 31, 2019
 
U.S.
 
International
 
Other
 
Consolidated
 
U.S.
 
International
 
Other
 
Consolidated
 
(In thousands)
NET REVENUE
$
7,068

 
$
7,467

 
$
—

 
$
14,535

 
$
6,766

 
$
6,124

 
$
—

 
$
12,890

COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION
(759
)
 
(1,168
)
 
—

 
(1,927
)
 
(685
)
 
(915
)
 
—

 
(1,600
)
GROSS PROFIT
6,309

 
6,299

 
—

 
12,608

 
6,081

 
5,209

 
—

 
11,290

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES
1,922

 
893

 
68

 
2,883

 
1,427

 
1,170

 
130

 
2,727

GENERAL AND ADMINISTRATIVE EXPENSES
1,973

 
936

 
272

 
3,181

 
1,933

 
988

 
472

 
3,393

SALES AND MARKETING EXPENSES
4,280

 
1,292

 
100

 
5,672

 
4,041

 
1,705

 
167

 
5,913

DEPRECIATION AND AMORTIZATION
—

 
—

 
654

 
654

 
—

 
—

 
652

 
652

OPERATING EXPENSES
8,175

 
3,121

 
1,094

 
12,390

 
7,401

 
3,863

 
1,421

 
12,685

SEGMENT (LOSS) INCOME FROM OPERATIONS

(1,866
)
 
3,178

 
(1,094
)
 
218

 
(1,320
)
 
1,346

 
(1,421
)
 
(1,395
)
OTHER INCOME AND EXPENSES, NET
—

 
—

 
(1,373
)
 
(1,373
)
 
—

 
—

 
(1,297
)
 
(1,297
)
NET LOSS BEFORE TAXES
 
 
 
 
 
 
$
(1,155
)
 
 
 
 
 
 
 
$
(2,692
)






RECONCILIATION OF GAAP MEASURES TO NON-GAAP ADJUSTED MEASURES
GAAP NET LOSS TO NON-GAAP ADJUSTED EBITDA
(in thousands)
 
Three Months Ended
March 31,
 
2020
 
2019
 
(Unaudited)
 
 
 
 
 
 
 
 
 
 
 
 
GAAP NET LOSS
$
(1,198)
 
$
(2,763)
Adjustments to net loss:
 
 
 
Interest expense and other
1,292
 
1,228
Provision for taxes
43
 
71
Depreciation and amortization
654
 
652
Stock-based compensation expenses
440
 
770
Unrealized foreign currency exchange losses
81
 
69
NON-GAAP ADJUSTED EBITDA
$
1,312
 
$
27